The global custom antibody market was valued at USD 409.31 million in 2021 and it is predicted to surpass around USD 833.96 million by 2030 with a CAGR of 8.23% from 2022 to 2030.
The global custom antibody market was valued at USD 409.31 million in 2021 and it is predicted to surpass around USD 833.96 million by 2030 with a CAGR of 8.23% from 2022 to 2030.
A custom antibody is designed or produced by the supplier for a specific antigen with the help of 90% purified antigen. Polyclonal and monoclonal antibodies are produced using custom antibody production. The steps of custom polyclonal antibody production are peptide design, designing of peptides, animal immunization, serum collection, titer analysis, and antibody purification. The steps for custom monoclonal antibody production are antigen preparation, immunizations of hybridoma development, hybridoma development fusions, monoclonal production and purification. The custom antibody has better selectivity compared to the normal cultured antibodies.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39762
Custom Abs have a wide range of applications in treating asthma, autoimmune diseases, cancer, poisoning, septicemia, viral infection, and other diseases. The prevalence of these diseases is increasing globally which boosts the market. The treatment with these antibodies is cost-effective. So hospitals and healthcare providers have a high demand for these antibodies accelerating the market growth. Some of the successfully developed custom antibodies are proteins and mixtures, membrane proteins, peptides, methylated antigens, phosphorylated antigens, haptens and small organic molecules.
Moreover, custom antibody production services are used to create and discover new biomarkers which also has a positive impact on the growing market. The growth of personalized medicines has also increased for the treatment of cancer and other chronic diseases. This enhances the usage of custom antibodies, thus driving market growth. In June 2021, a custom rabbit mAB, MonoRab was launched by GenScript. It involves hybridoma technology and mAB sequencing. It has better specificity and better affinity applicable to a wide range of applications. The changing disease profiles, growing government funding and support, advances in biotechnology research, and rising public and private partnerships boost market growth.
The market is segmented based on the type, service, source, application, end user, and region. The type segment is divided into monoclonal antibodies, polyclonal antibodies, and recombinant antibodies. The service segment is divided into antibody development, antibody production and purification, antibody fragmentation and labeling. The source segment is divided into mice and rabbits. The application segment is divided into oncology, infectious diseases, immunology, neurobiology, stem cells, and cardiovascular diseases. The end-user segment is divided into pharma and biotechnology companies, hospitals and clinics, and contract research organizations. Based on regions, the market is further segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
As per the regional analysis research, North America holds the largest market due to the advanced healthcare and research facilities available. In this region the government and biotechnology companies are focused on the advancements of drug design structure, research activities, improvement in the proteomics and genomics sector and increasing development in the therapeutics based on antibodies. The majority of the key players are also present in North America which is the major driving factor for enhancing the market. Asia-Pacific region also holds a significant market due to the improved infrastructure of the healthcare facilities, and better healthcare reimbursement policies. Moreover, the therapeutics industry is also growing in the regions of India and China which spurs the market growth.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 409.31 million |
| Revenue Forecast by 2030 | USD 833.96 million |
| Growth rate from 2022 to 2030 | CAGR of 8.23% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, Service, Source, Application, End user, Region |
| Companies Covered | Thermo Fisher Scientific Inc., Merck KGaA, Cell Signaling Technology Inc., Rockland Immunochemicals, BioLegend, GenScript, Bio-Rad Laboratories Inc., Abcam PLC, Agilent Technologies, Innovagen Ab, ProMab Biotechnologies, Proteogenix, among others |
Key Findings
- Based on service, the custom antibody market is segmented into antibody development, antibody production and purification, and antibody fragmentation and labelling. In 2020, the antibody development segment held the largest share of the market, and is estimated to grow at significant CAGR during the forecast period.
- Based on type, the custom antibody market is segmented into monoclonal antibodies, polyclonal antibodies, and other custom antibodies. In 2020, the monoclonal antibodies segment held the largest share of the market, whereas the polyclonal antibodies segment is expected to grow during the forecast period.
- Based on source, the custom antibody market is segmented into mice, rabbit, and others. The mice segment held the largest share of the market in 2020, whereas the mice segment is anticipated to register the highest CAGR in the market during the forecast period.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39762
Market Growth & Trends
The growth of the custom antibody market is driven by increasing awareness and quality concerns regarding antibodies. Moreover, the escalating awareness about personalized therapeutics is the market growth trend. In addition, the massive requirement for substantial capital funding in research activities about the production of antibodies is also helping to boost the market growth during the forecast period. Further, the increasing occurrence of contagious ailments, the surge in the research activities in life sciences & biotechnology, and growing public-private partnerships propel market growth. The other factor also includes the high adoption in developed markets, an increase in the prevalence of different types of cancer, and the development of innovative drugs are propelling market growth.
Key Players
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Rockland Immunochemicals
- BioLegend
- GenScript
- Bio-Rad Laboratories Inc.
- Abcam PLC
- Agilent Technologies
- Innovagen Ab
- ProMab Biotechnologies
- Proteogenix
- others
Market Segmentation
- By Type
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies
- By Service
- Antibody Development
- Antibody Production & Purification
- Antibody Fragmentation & Labeling
- By Source
- Rabbit
- Mice
- By Application
- Oncology
- Infectious Disease
- Immunology
- Neurobiology
- Stem Cells
- Cardiovascular Disease
- By End user
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Contract Research Organizations
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39762
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/